BioSpace: LongeVC's Sergey Jakimov and Artem Trotsyuk on Why Validated Mechanisms Beat Hype in Longevity Investing
LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk were featured in BioSpace, sharing their perspective on what it takes to build a credible longevity company in today's investment landscape.
In a discussion with Jennifer C. Smith-Parker, Sergey and Artem argued that the field's early stumbles were not due to weak science, but to an unfocused approach that treated aging as a vague, monolithic goal rather than a set of specific, measurable conditions. The path forward, they said, lies in targeting concrete disease indications with mechanistic clarity - and building evidence strategies that speak the language of regulators and payers from day one.